Infinity will not go beyond Phase II with retaspimycin
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals ended development for its selective heat shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride following a failed Phase II lung cancer study and will focus instead on IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
You may also be interested in...
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.